Home Current Issue Previous Issues Published Ahead-of-Print For Authors Journal Info
Skip Navigation LinksHome > July 2008 - Volume 23 - Issue 4 > Methylphenidate in the treatment of female adolescents with...
International Clinical Psychopharmacology:
doi: 10.1097/YIC.0b013e3282f94ae2
Original Articles

Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial

Golubchik, Pavela b; Sever, Jonathana b; Zalsman, Gila b; Weizman, Abrahama b c

Collapse Box


Recent studies reported symptomatic overlap between attention deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD). Methylphenidate (MPH) is the most efficient treatment for ADHD. We assessed the efficacy and tolerability of MPH treatment in adolescent females who met the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for both disorders. Fourteen BPD/ADHD female adolescents aged 14–19 years were treated with MPH for 12 weeks, targeting ADHD, BPD symptoms, and aggressive behavior, as rated by ADHD-rating scale (ADHD-RS) and Clinical Global Impression-Severity (CGI-S) scale for BPD and aggressive behavior severity. A significant improvement was detected in both ADHD and BPD severity (baseline vs. end point, ADHD-RS: 33.1±4.8 vs. 17.6±5.2, P<0.001; BPD CGI-S: 4.6±0.8 vs. 3.4±0.8, P<0.0005, respectively) as well as in aggressive behavior (Aggression CGI-S: 3.5±1.3 vs. 1.8±0.5, P<0.001). MPH was well tolerated. MPH may be useful and well tolerated in treating some shared symptoms of ADHD and BPD among female adolescents. Controlled studies are needed to substantiate these findings.

© 2008 Lippincott Williams & Wilkins, Inc.


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.